Ivosidenib for advanced IDH1-mutant cholangiocarcinoma

Lancet Oncol. 2020 Aug;21(8):e370. doi: 10.1016/S1470-2045(20)30343-0.

Authors

Lorenzo Gervaso¹, Stefania Pellicori¹, Nicola Fazio²

Affiliations

¹ Division of Gastrointestinal Medical Oncology and Neuroendocrine Tumors, European Institute of Oncology, 20141 Milan, Italy.
² Division of Gastrointestinal Medical Oncology and Neuroendocrine Tumors, European Institute of Oncology, 20141 Milan, Italy. Electronic address: nicola.fazio@ieo.it.

PMID: 32758465
DOI: 10.1016/S1470-2045(20)30343-0

No abstract available

Publication types

Letter
Comment

MeSH terms

Bile Duct Neoplasms*
Bile Ducts, Intrahepatic*
Cholangiocarcinoma*
Double-Blind Method
Glycine / analogs & derivatives
Humans
Isocitrate Dehydrogenase
Pyridines

Substances

Pyridines
Isocitrate Dehydrogenase
IDH1 protein, human
ivosidenib
Glycine